CA
NZ
UK
AU
IND
US
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) shares traded at $11.09, up 0.91% on the day, after the company shared two-year Phase 2b PRISM trial data for 4D-150 in wet age-related macular degeneration (AMD) at the ASRS meeting.
PolyPid Ltd. (NASDAQ: PYPD) shares fell approximately 8% despite the company forming an exclusive commercial alliance with Azurity Pharmaceuticals for the U.S. and Canadian commercialization of D-PLEX100, aimed at preventing abdominal surgical site infections (SSIs).
Agios Pharmaceuticals (NASDAQ: AGIO) shares fell approximately 13% in pre-market trading after the company revealed Phase 2 data for tebapivat in sickle cell disease (SCD) and announced it would halt the program.
Faeth Therapeutics (NASDAQ: FTH) shares closed up 9% at $28.19 after the company received a new Market Outperform rating from a Citizens analyst, who initiated coverage with a price target of $51.
Daré Bioscience (NASDAQ: DARE) shares closed down 32% at $1.34 after the company received formal notification from the Nasdaq Listing Qualifications Staff on July 13, 2026, regarding a deficiency in stockholders' equity.
Vyne Therapeutics (NASDAQ: VYNE) shares fell approximately 4% in pre-market trading after the company convened a special meeting of shareholders to deliberate on proposals tied to its merger with Yarrow.
Calidi Biotherapeutics (NYSE: CLDI) shares fell approximately 18% after the company disclosed a 1-for-16 reverse stock split scheduled to take effect on July 31, 2026.
Valion Bio (NASDAQ: VBIO) shares closed down 29% at $0.37 even after the company and Sheba Medical Center finalized an agreement to fund and execute a clinical trial of Entolimod.
Armata Pharmaceuticals (NYSE American: ARMP) shares closed up 12% at $5.06 after the company confirmed the submission of its Phase 3 superiority study protocol for AP-SA02, targeting Staphylococcus aureus bacteremia, following resolution of all FDA clinical and regulatory inquiries from its End-of-Phase 2 meeting.
OKYO Pharma Limited (NASDAQ: OKYO) disclosed that its Chairman, Gabriele Cerrone, increased his equity position through Panetta Partners Ltd.
Please wait processing your request...